Updated: FDA pushes to make opioid overdose reversal agents OTC products as companies balk
Members of Congress on both sides of the aisle have slammed the FDA for failing to take adequate action to help the skyrocketing death toll from opioid overdoses.
Taking that critique to heart, the FDA said Tuesday that it is moving forward with a previously hatched plan to make certain opioid overdose reversal agents (i.e. naloxone nasal sprays and autoinjectors) over-the-counter products, potentially increasing their availability.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.